| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
31,570,000 |
| Market
Cap: |
7.49(M) |
| Last
Volume: |
540,567 |
Avg
Vol: |
535,506 |
| 52
Week Range: |
$0.1483 - $0.94 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile BrainStorm Cell Therapeutics is a biotechnology company engaged in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases including: Amyotrophic Lateral Sclerosis; Progressive Multiple Sclerosis; Alzheimer's disease; and other neurodegenerative diseases. NurOwn®, Co.'s proprietary platform, utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
566,372 |
566,372 |
577,872 |
| Total Buy Value |
$0 |
$271,807 |
$271,807 |
$292,209 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
11 |
11 |
12 |
| Total Shares Sold |
63,000 |
63,000 |
63,000 |
63,000 |
| Total Sell Value |
$22,069 |
$22,069 |
$22,069 |
$22,069 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
1 |
1 |
1 |
1 |
| End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Almenoff June Sherie |
Director |
– • – |
2019-01-04 |
4 |
B |
$3.39 |
$5,000 |
I/I |
1,475 |
7,175 |
2.1 |
- |
|
| Taub Malcolm S |
Director |
– • – |
2018-11-30 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
41,332 |
|
- |
|
| Polverino Anthony J. |
Director |
– • – |
2018-11-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,667 |
7,290 |
|
- |
|
| Schor Chen |
Director |
– • – |
2018-11-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
125,558 |
|
- |
|
| Schor Chen |
Director |
– • – |
2018-10-24 |
4 |
GA |
$0.00 |
$0 |
I/I |
121,558 |
121,558 |
|
- |
|
| Schor Chen |
Director |
– • – |
2018-10-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
121,558 |
4,000 |
|
- |
|
| Araya Arturo |
Chief Commercial Officer |
• • – |
2018-08-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,805) |
5,608 |
|
- |
|
| Lebovits Chaim |
See Remarks |
• – – |
2018-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
31,185 |
2,134,970 |
|
- |
|
| Araya Arturo |
Director |
– • – |
2018-03-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,249 |
8,413 |
|
- |
|
| Kern Ralph Dr. |
COO and Chief Medical Officer |
• – – |
2018-03-15 |
4/A |
B |
$3.60 |
$17,997 |
D/D |
5,000 |
40,885 |
2.74 |
- |
|
| Almenoff June Sherie |
Director |
– • – |
2018-03-15 |
4/A |
B |
$3.50 |
$19,950 |
I/I |
5,700 |
5,700 |
2.1 |
- |
|
| Kern Ralph Dr. |
COO and Chief Medical Officer |
• – – |
2018-03-15 |
4 |
A |
$3.60 |
$17,997 |
D/D |
5,000 |
40,885 |
|
- |
|
| Almenoff June Sherie |
Director |
– • – |
2018-03-15 |
4 |
A |
$3.50 |
$19,950 |
I/I |
5,700 |
5,700 |
|
- |
|
| Kern Ralph Dr. |
COO and Chief Medical Officer |
• – – |
2018-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
35,885 |
76,770 |
|
- |
|
| Polverino Anthony J. |
Director |
– • – |
2018-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,623 |
3,623 |
|
- |
|
| Rubin Eyal |
CFO and Treasurer |
• – – |
2017-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
|
- |
|
| Taub Malcolm S |
Director |
– • – |
2017-11-10 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
29,332 |
|
- |
|
| Shorr Robert G L |
Director |
– • – |
2017-11-10 |
4 |
A |
$0.00 |
$0 |
D/D |
8,666 |
45,731 |
|
- |
|
| Schor Chen |
Director |
– • – |
2017-11-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
123,558 |
|
- |
|
| Arbel Irit |
Director |
– • – |
2017-08-31 |
4 |
B |
$4.26 |
$10,650 |
D/D |
2,500 |
155,833 |
2.39 |
- |
|
| Yablonka Uri |
EVP & Chief Business Officer |
• • – |
2017-08-23 |
4 |
B |
$3.98 |
$7,960 |
D/D |
2,000 |
7,543 |
2.81 |
- |
|
| Lebovits Chaim |
See Remarks |
• – – |
2017-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
31,185 |
2,103,785 |
|
- |
|
| Yablonka Uri |
EVP & Chief Business Officer |
• • – |
2017-07-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,543 |
5,543 |
|
- |
|
| Araya Arturo |
Director |
– • – |
2017-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,012 |
3,012 |
|
- |
|
| Taub Malcolm S |
Director |
– • – |
2016-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,666 |
17,332 |
|
- |
|
131 Records found
|
|
Page 4 of 6 |
|
|
0.01 (2.35%) 
